Alamar Biosciences said it will use its Nulisa platform to collaborate with GlaxoSmithKline to study circulating protein characteristics and disease progression. Alamar said the study will examine the relationship between circulating protein characteristics and disease progression, biological subtypes, and treatment response, covering respiratory, liver, kidney, neurological, and autoimmune conditions.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.